论文部分内容阅读
水难溶性抗癌药物的非胃肠道给药所面临的主要问题是这些药物与水、盐溶液或血液混合即析出沉淀。使药物不为生物所利用,同时还可引起疼痛或静脉炎。因此药物在加入水中时必须一段时间内保持溶液状态。本文提出了一个用于水难性药物的注射用赋形剂,主要是采用普郎尼克(Pluronic)L 64形成的助溶体系,它对三种水难溶性抗癌药物有良好的增溶作用。三种药物分别为Taxol(NSC 125973);3,5-二氯-2,4-二甲氧基-6-三氯甲基吡啶(NSC 0338720)及2-S-氯甲基-巯基喹啉。
The main problem with parenteral administration of poorly water-soluble anticancer drugs is the precipitation of these drugs when mixed with water, saline or blood. So that drugs are not used by biological, but can also cause pain or phlebitis. Therefore, the drug must remain in solution for a period of time while it is added to the water. In this paper, an excipient for injecting drugs of poor water quality is proposed, mainly consisting of a solubilizing system formed by Pluronic L64, which has good solubilization effects on three water-insoluble anticancer drugs . The three drugs are Taxol (NSC 125973), 3,5-dichloro-2,4-dimethoxy-6-trichloromethyl pyridine (NSC 0338720) and 2-S- chloromethyl-mercaptoquinoline .